PKPravin Kamble

Pravin Kamble

*This is an algorithmically generated author record based on publicly available information.

Pravin Kamble has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn’s Disease: Results From the EVOLVE Expansion Study

    by Britt Christensen, Michael Scharl, Brian Bressler, Zaeem Khan, Yuliya Halchenko, Celine Gisler, Pravin Kamble, Shashi Adsul, Zeinab Farhat, Marc Ferrante

    Background: We evaluated the real-world effectiveness and safety of vedolizumab and ustekinumab as first-line biologics in patients with Crohn’s disease (CD), by disease duration. Methods: EVOLVE Expansion (ClinicalTrials.gov, NCT05056441) was a retrospective medical chart review study in Australia, Belgium, and Switzerland. Biologic-naïve patients with CD (≥18 years old) initiated first-line biologic treatment with vedolizumab or ustekinumab. Cumulative rates of clinical response, remission, mucosal healing, and treatment persistence were assessed over 36 months. Outcomes were compared between patients with early (≤2 years) and late (>2 years) disease at biologic initiation. Serious adverse events (SAEs), serious infections (SIs), and healthcare resource use (HCRU) were evaluated. Results: In early (n = 249) and late (n = 371) CD subgroups, there were no significant differences over 36 months between vedolizumab and ustekinumab in the cumulative rates of clinical response (early CD, 81.6% vs 80.7%; P = .31; late CD, 83.7% vs 86.5%; P = .31) or clinical remission (early CD, 87.9% vs 85.0%; P = .74; late CD, 91.1% vs 90.6%; P = .96). In patients with early CD, mucosal healing rates were significantly higher with vedolizumab than ustekinumab at both 24 (P = .02) and 36 months (P = .03). Treatment persistence was significantly higher with ustekinumab versus vedolizumab over 36 months in patients with late CD, but similar in patients with early CD. There were no significant differences in SAEs, SIs, or HCRU. Conclusions: Both vedolizumab and ustekinumab are effective treatment options for early- and late-stage CD. Over 36 months, mucosal healing rates in patients with early CD were significantly higher with vedolizumab than with ustekinumab.


  • Open Access

    Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn’s Disease

    by Andres J. Yarur, Brian Bressler, Neil R. Brett, Marielle Ba Bassel, Shashi Adsul, Pravin Kamble, Gerassimos J. Mantzaris

    Goals: This study evaluated the real-world effectiveness and safety of vedolizumab versus adalimumab over 12 months of treatment in biologic-naive patients with Crohn’s disease (CD), using data from the EVOLVE study. Background: A comparison of vedolizumab and adalimumab may help to better position them in the therapeutic algorithm for moderate-to-severe CD. Study: Data were collected from medical records of patients with CD aged ≥18 years initiating treatment with adalimumab or vedolizumab between May 2014 and July 2017. Adjusted analyses were performed using inverse probability weighting to account for differences in baseline characteristics. Cumulative rates for clinical effectiveness outcomes and treatment persistence were estimated using Kaplan-Meier analyses. Disease-related exacerbations, serious adverse events (SAEs), and serious infections (SIs) were also assessed. Results: Data from 218 vedolizumab- and 144 adalimumab-treated patients were analyzed. Adjusted cumulative rates of clinical remission were greater with vedolizumab than with adalimumab (66.3% vs. 46.4%; P=0.006). Probability of treatment persistence was higher with vedolizumab (89.3% vs. 77.5%; P=0.024); probabilities of clinical response (68.5% vs. 61.1%; P=0.586) and mucosal healing (67.7% vs. 56.0%; P=0.562) were similar. SAEs were less likely to occur with vedolizumab [hazard ratio, 0.45 (95% confidence interval, 0.22-0.93)]; however, the likelihood of SIs [0.27 (0.06-1.20)], CD exacerbations [0.91 (0.56-1.47)], and CD-related surgeries [1.55 (0.21-11.15)] was comparable between the 2 groups. Conclusions: In a real-world setting, biologic-naive patients with CD treated with vedolizumab demonstrated a greater likelihood of drug persistence and achieving clinical remission, with equivalent rates of response and mucosal healing versus adalimumab-treated patients.


  • Open Access

    Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn’s disease: results from the EVOLVE study

    by Gerassimos J. Mantzaris, Brian Bressler, Shashi Adsul, Michelle Luo, Chris Colby, Neil R. Brett, Sumit Saha, Pravin Kamble, Song Wang, Andres Yarur

    Objectives: This study compared the real-world effectiveness and safety of α4β7-integrin inhibitor vedolizumab and anti-tumor necrosis factor alpha (anti-TNFα) inhibitor infliximab in biologic-naive patients with Crohn’s disease (CD). Methods: EVOLVE was a retrospective, multicenter, medical chart review of biologic-naive adults with inflammatory bowel disease receiving vedolizumab or anti-TNFα treatment as first-line biologics in Canada, Greece, and the USA. Twelve-month outcomes were analyzed in vedolizumab- or infliximab-treated patients with moderate-to-severe CD (and subgroups with complicated and noncomplicated CD) including cumulative rates of clinical response, clinical remission, and mucosal healing, and incidence rates of serious adverse events (SAEs) and serious infections (SIs). Inverse probability weighting (IPW) was used to account for baseline differences between treatment groups. Results: Data were analyzed from 167 patients. In the IPW dataset (99 vedolizumab-treated and 63 infliximab-treated), adjusted 12-month clinical remission rates were 73.1% and 55.2%, respectively (P = 0.31). Overall, effectiveness rates were similar across treatment and complicated/noncomplicated disease subgroups. Adjusted 12-month incidence rates (first occurrence/1000 person-years) of SAEs for vedolizumab vs. infliximab: 43.6 vs. 200.9 [hazard ratio (HR) 0.36 (0.09–1.54)]; SIs: 10.8 vs. 96.0 [HR 0.08 (<0.01–2.64)]. AE incidence was significantly lower in vedolizumab- vs. infliximab-treated patients for complicated [131.6 vs. 732.2; HR 0.19 (0.05–0.65)] and noncomplicated [276.3 vs. 494.8; HR 0.59 (0.35–0.99)] disease subgroups. Conclusion: These real-world data on first-line biologics show no differences in 12-month effectiveness outcomes for vedolizumab- vs. infliximab-treated biologic-naive patients with CD. Vedolizumab may have a more favorable safety profile vs. infliximab in patients with complicated and noncomplicated disease.


  • Open Access

    Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review

    by Dipen Patel, Stephan Martin, Michelle Luo, Lyann Ursos, Richard A Lirio, Pravin Kamble, Song Wang

    Background: Vedolizumab is a gut-selective anti-lymphocyte trafficking agent approved for the treatment of moderate to severely active inflammatory bowel disease (IBD: ulcerative colitis [UC] and Crohn’s disease [CD]). Methods: A systematic literature review (SLR) of real-world studies was conducted to assess the effectiveness of dose escalation of vedolizumab every 8 weeks (Q8W) during maintenance treatment to achieve a response in patients who were either vedolizumab responders experiencing secondary loss of response (SLOR) or non-responders. MEDLINE and EMBASE databases were searched from January 2014 to August 2021. Results: Screening of SLR outputs identified 72 relevant real-world study publications featuring dose escalation of vedolizumab maintenance therapy. After qualitative review, ten eligible studies (9 articles, 1 abstract) were identified as reporting clinical response and/or clinical remission rates following escalation of intravenous vedolizumab 300 mg Q8W maintenance dosing to every 4 weeks (Q4W) maintenance dosing in adult patients with UC/CD (≥10 patients per study). Overall, 196/395 (49.6%) patients with IBD had a response within 54 weeks of vedolizumab maintenance dose escalation. Although definitions for clinical response/remission varied across the 10 studies, clinical response rates after escalated vedolizumab Q8W maintenance dosing ranged from 40.0% to 73.3% (9 studies) and from 30.0% to 55.8% for remission (4 studies) over a range of 8 to <58 weeks’ follow-up. Conclusions: This synthesis of real-world effectiveness data in vedolizumab-treated patients with IBD indicates that approximately half were able to achieve or recapture clinical response after escalating vedolizumab maintenance dosing.


  • Open Access

    Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn’s Disease

    by Silvio Danese, Pravin Kamble, Jin Yang, Jean-Gabriel Le Moine, Shahnaz Khan, Emma Hawe, Christian Agboton, Song Wang, Peter M. Irving

    Background. Vedolizumab is a gut-selective monoclonal anti-α4β7-integrin antibody approved for the treatment of adults with moderately to severely active Crohn’s disease (CD). Aim. To conduct a systematic literature review and meta-analysis of published real-world studies examining mucosal healing (MH) rates in patients with CD treated with vedolizumab in routine clinical practice. Methods. MEDLINE-, Cochrane-, and EMBASE-indexed publications from January 2014 to January 2020 and 2018-2019 conference abstracts were searched for real-world studies reporting MH-related outcomes in vedolizumab-treated adults with CD. A meta-analysis was conducted in R to generate pooled estimates of MH. The primary analysis included studies reporting point estimates of MH/endoscopic remission as absence of ulcers/erosions and/or Simple Endoscopic Score for CD (SES-CD) cut − points < 4 , at 6 and 12 months. Results. The systematic literature review included 36 studies, predominantly of antitumour necrosis factor-experienced patients. MH and endoscopic remission were the most frequently reported endpoints. MH rates were 10.1%-46.0% at 6 months (ten studies) and 21.2%-62.5% at 12 months (eight studies). Fifteen studies defining MH as absence of ulcers/erosions and/or SES-CD cut − points < 4 were included for meta-analysis. Pooled MH rates for the primary analysis were 31.8% at 6 months (95% confidence interval (CI): 25.6-38.3; five studies, N = 223 ) and 33.4% at 12 months (95% CI: 25.9-41.4; three studies, N = 151 ). Conclusion. Approximately one-third of vedolizumab-treated patients with CD achieved MH at both 6 and 12 months in real-world clinical settings, despite utilisation in largely biologic-refractory patients. These findings confirm the effectiveness of vedolizumab for achieving MH in patients with CD.


  • Metabolische Effekte einer Kombination von Dapagliflozin und wöchentlichem Exenatide bei adipösen Erwachsenen ohne Diabetes: 24-wöchige, randomisierte, placebokontrollierte Phase-2-Studie

    by P Lundkvist, S Amini, J Lau Börjesson, Mj Pereira, P Kamble, D Sjöström, E Johnsson, Jw Eriksson, C Klisch

    Hintergrund: In einer verblindeten, placebokontrollierten Phase-2-Studie wurde Dapagliflozin (DAPA) in Kombination mit Exenatide (EXE) bei übergewichtigen Erwachsenen mit unauffälligem Glukosestoffwechsel, abnormer Nüchternglukose (IFG, Nüchternglukose ≥5,6 mmol/l) oder eingeschränkter Glukosetoleranz (IGT) untersucht. Eine stärkere Reduktion von Körpergewicht, vor allem durch Verlust von Fettgewebe, sowie von HbA1c und Nüchternglukose, des Anteils Patienten mit IFG bzw. IGT sowie der Glukose-AUC im OGTT wurde bereits auf dem ADA 2016 vorgestellt. Hier werden zusätzliche Ergebnisse präsentiert, die den Lipidstoffwechsel betreffen. Methodik: In einer monozentrischen, 1:1 randomisierten, 24-wöchigen, doppelblinden Studie erhielten 50 adipöse (BMI 30 – 45 kg/m2) Erwachsene ohne Diabetes zwischen 18 und 70 Jahren randomisiert entweder 10 mg/d DAPA und 2 mg/Woche EXE (n = 25) oder entsprechende Placebos (n = 25). Es wurden ein Ganzkörper-MRT erstellt und anthropometrische Daten, sowie Laborwerte nüchtern und zum Zeitpunkt 3 Stunden im oralen Glukosetoleranztest (oGTT) erfasst. Ergebnisse: Die AUC freier Fettsäuren (FFA) im oGTT nahm im Vergleich zum Ausgangswert unter DAPA+EXE um 19% zu, die AUCs von Insulin und Glycerol sowie ß-Hydroxyketone zeigten keine signifikanten Veränderungen. Insulinsekretion und Insulinsensitivität änderten sich ebenfalls nicht. In keiner Behandlungsgruppe änderten sich Triglyceride, Gesamtcholesterin, LDL-Cholesterin oder HDL-Cholesterin. Unerwünschte Ereignisse entsprechen den Nebenwirkungsprofilen der beiden Wirkstoffe. Schlussfolgerung: In dieser Phase-2-Studie mit adipösen Probanden ohne Diabetes führte die Kombinationstherapie mit DAPA+EXE gegenüber PBO zu einer signifikanten Reduktion von Gewicht, HbA1c und Glukosespiegel nach Provokation. IFG und IGT zeigten sich weitgehend normalisiert. Diese Wirkungen traten ohne signifikante Veränderungen der geschätzten Insulinsensitivität und der Betazellfunktion auf. Der FFA-Anstieg spricht möglicherweise für eine vermehrte Energiegewinnung aus Fettsäuren nach Lipidmobilisierung.